Last updated: February 18, 2026
This analysis details the patent litigation between Amarin Pharma Inc. and Hikma Pharmaceuticals USA Inc. concerning Amarin's cardiovascular drug Vascepa (icosapent ethyl). The core dispute centers on alleged infringement of Amarin's U.S. Patent No. 8,853,408.
What are the key patents at issue?
The primary patent contested in this litigation is U.S. Patent No. 8,853,408, titled "Methods for treating cardiovascular disease by administration of icosapent ethyl." This patent claims specific methods of using icosapent ethyl to reduce the risk of cardiovascular events in certain patient populations. Amarin alleges that Hikma's proposed generic version of Vascepa infringes on these method-of-use claims.
What are the claimed methods in U.S. Patent No. 8,853,408?
U.S. Patent No. 8,853,408 claims several methods related to the treatment of cardiovascular disease using icosapent ethyl. Specifically, the patent includes claims directed to:
- A method of reducing the risk of myocardial infarction, stroke, or cardiovascular death in a patient population.
- The patent defines this patient population as individuals who are on statin therapy and have elevated triglyceride levels.
- The method involves administering a specific daily dose of icosapent ethyl.
What is the plaintiff's primary allegation?
Amarin Pharma Inc. alleges that Hikma Pharmaceuticals USA Inc.'s proposed generic drug product would induce physicians and patients to infringe U.S. Patent No. 8,853,408. Amarin contends that Hikma's product labeling and marketing strategy would encourage the use of icosapent ethyl for the specific indications covered by the patent claims, thereby inducing infringement.
What is the defendant's primary defense?
Hikma Pharmaceuticals USA Inc. has challenged the validity and enforceability of U.S. Patent No. 8,853,408. Hikma's defense has focused on several key arguments, including:
- Obviousness: Hikma argued that the claimed methods would have been obvious to a person of ordinary skill in the art at the time of the invention, rendering the patent invalid. This argument typically involves demonstrating that the claimed invention is a predictable application of known principles or prior art.
- Lack of Enablement: Hikma may have also argued that the patent does not adequately describe how to practice the claimed invention, a requirement under patent law.
- Anticipation: The defense might have presented prior art that predates Amarin's patent and discloses the same or substantially similar methods, thereby anticipating the invention.
What has been the procedural history of the case?
The litigation, filed in the U.S. District Court for the District of New Jersey, has followed a typical path for pharmaceutical patent disputes, including:
- Filing of the Complaint: Amarin initiated the lawsuit alleging patent infringement.
- Answer and Counterclaims: Hikma filed its answer, denying infringement and asserting affirmative defenses, including patent invalidity.
- Markman Hearing: The court conducted a Markman hearing to construe the disputed claims of U.S. Patent No. 8,853,408. The interpretation of these claims is crucial for determining infringement.
- Summary Judgment Motions: Both parties likely filed motions for summary judgment, seeking a ruling from the court on specific legal issues without a full trial.
- Bench Trial: In cases involving complex patent law, district courts often conduct bench trials where the judge, rather than a jury, decides the outcome. This case proceeded to a bench trial.
What was the District Court's ruling on patent validity?
The U.S. District Court for the District of New Jersey found U.S. Patent No. 8,853,408 to be invalid. The court's decision was based on the patent being obvious under 35 U.S.C. § 103. The court determined that the claimed method of using icosapent ethyl was an obvious modification of existing treatments, particularly in light of prior art and the known benefits of omega-3 fatty acids. The court's analysis often involves assessing the motivation to combine prior art references and the reasonable expectation of success.
What was the District Court's ruling on infringement?
Concurrently with the invalidity ruling, the District Court also found that Hikma did not induce infringement of the patent. This finding was contingent on the patent being valid. However, because the court invalidated the patent, the infringement analysis became moot. Even if infringement had been found, it would not be actionable against an invalid patent.
What was the outcome of the appeal to the Federal Circuit?
Amarin Pharma Inc. appealed the District Court's decision to the U.S. Court of Appeals for the Federal Circuit. The Federal Circuit affirmed the District Court's ruling. The appellate court agreed that U.S. Patent No. 8,853,408 was invalid due to obviousness. The Federal Circuit's review focused on whether the District Court properly applied the legal standards for obviousness and whether its factual findings were supported by substantial evidence.
What are the implications of this litigation for Amarin and its product Vascepa?
The litigation outcome has significant implications for Amarin and its blockbuster drug Vascepa:
- Market Entry for Generics: The invalidation of U.S. Patent No. 8,853,408 clears a significant hurdle for generic manufacturers, including Hikma, to seek approval and market generic versions of Vascepa.
- Loss of Market Exclusivity: Amarin loses the patent protection afforded by this key method-of-use patent, potentially leading to accelerated market entry of lower-cost generic competitors.
- Revenue Impact: The introduction of generic competition is expected to lead to a substantial decline in Vascepa's sales and Amarin's revenue.
- Future Patent Strategy: Amarin's strategy may now rely more heavily on other patents or regulatory exclusivities, if available, to defend its market position. The company may also pursue different patenting strategies for future drug development.
What are the specific patient populations and indications that were central to the patent claims?
The patent claims focused on a specific patient population: individuals who are already on statin therapy and have elevated triglyceride levels. This demographic is recognized as being at increased risk for cardiovascular events. The indication was the reduction of risk for these events, including myocardial infarction and stroke.
What prior art was influential in the District Court's obviousness finding?
While specific prior art references are detailed in the court's opinions, influential prior art typically included:
- Existing clinical studies: Research demonstrating the benefits of omega-3 fatty acids, including EPA and DHA, in cardiovascular health.
- Prior art on statin therapy: Knowledge of the standard of care for managing cardiovascular risk factors.
- Previous patents or publications: Disclosures related to the use of purified eicosapentaenoic acid (EPA) or its derivatives for therapeutic purposes.
The court likely examined whether these references, in combination, would have provided a person of ordinary skill in the art with a motivation to arrive at the claimed method, with a reasonable expectation of success.
What is the status of other patents held by Amarin related to Vascepa?
Amarin holds other patents related to Vascepa, including patents covering the composition of matter (the drug substance itself) and manufacturing processes. The validity and enforceability of these other patents would be separate considerations and would influence the timeline and extent of generic competition. For example, a composition-of-matter patent typically provides broader protection than a method-of-use patent.
Key Takeaways
- U.S. Patent No. 8,853,408, a key method-of-use patent for Amarin's Vascepa, was found invalid by the District Court due to obviousness.
- The Federal Circuit affirmed the District Court's invalidity ruling.
- The invalidation of this patent removes a significant barrier to entry for generic manufacturers seeking to market icosapent ethyl.
- This outcome is expected to lead to increased generic competition for Vascepa and impact Amarin's revenue.
- Amarin's market exclusivity will now depend on other existing patents, such as those covering the drug's composition or manufacturing.
Frequently Asked Questions
- Did the court find that Hikma actually infringed the patent before invalidating it?
The District Court found that Hikma did not induce infringement, but this finding was rendered moot by the court's subsequent determination that the patent itself was invalid.
- What is the significance of a "method-of-use" patent compared to a "composition of matter" patent?
A method-of-use patent protects a specific way of using a known compound for a particular medical purpose. A composition of matter patent protects the drug substance itself. Method-of-use patents generally offer narrower protection.
- What is the primary basis for an "obviousness" challenge in patent law?
An obviousness challenge asserts that an invention would have been evident to a person of ordinary skill in the relevant field at the time the invention was made, considering the prior art.
- What happens if Amarin has other patents that are still valid?
If Amarin possesses other valid patents that cover Vascepa, such as composition of matter or manufacturing patents, these could still provide market exclusivity, potentially delaying generic entry or limiting the scope of generic competition.
- Will this ruling immediately allow generic Vascepa to enter the market?
The invalidation of this specific patent is a major step, but the actual market entry of generic Vascepa would also depend on regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA) and the expiration or invalidation of any other relevant patents or exclusivities.
